Management of encapsulating peritoneal sclerosis: A guideline on optimal and uniform treatment

Netherlands Journal of Medicine

Volumn 69, Issue 11, 2011, Pages 500-507

  Habib, S M ^a   Betjes, M G H ^a   Fieren, M W J A ^a   Boeschoten, E W ^c   Abrahams, A C ^d   Boer, W H ^d   Struijk, D G ^e   Ruger, W ^f   Krikke, C ^g   Westerhuis, R ^g   de Sevaux R G L ^h   van der Sande, F M ⁱ   Gaasbeek, A ^j   Korte, M R ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ALBERT SCHWEITZER HOSPITAL   (Netherlands)

^c Hans Mak Institute   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

^f VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^g UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^h RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁱ MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^j LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

Encapsulating peritoneal sclerosis; Enterolysis; Immune suppressive; Management algorithm; Peritoneal dialysis

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RAPAMYCIN; TAMOXIFEN;

ALGORITHM; ANGIOGENESIS; CLINICAL EVALUATION; CLINICAL TRIAL; ENDOMETRIUM CARCINOMA; HOT FLUSH; HUMAN; INFLAMMATION; LUNG EMBOLISM; MESOTHELIUM CELL; PATHOGENESIS; PERITONEAL DIALYSIS; PERITONEAL FIBROSIS; PRACTICE GUIDELINE; REVIEW; STROKE; THROMBOEMBOLISM; TOTAL PARENTERAL NUTRITION; UNSPECIFIED SIDE EFFECT;

COMBINED MODALITY THERAPY; HUMANS; PERITONEAL DIALYSIS; PERITONEAL FIBROSIS;

EID: 83755186395     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (84)

1. Honda K, Oda H. Pathology of encapsulating peritoneal sclerosis. Perit Dial Int. 2005;25 Suppl 4:S19-29.
2. Rigby RJ, Hawley CM. Sclerosing peritonitis: the experience in Australia. Nephrol Dial Transplant. 1998;13:154-9.
3. Kawanishi H, Kawaguchi Y, Fukui H, et al. Encapsulating peritoneal sclerosis in Japan: a prospective, controlled, multicenter study. Am J Kidney Dis. 2004;44:729-37.
4. Habib AM, Preston E, Davenport A. Risk factors for developing encapsulating peritoneal sclerosis in the icodextrin era of peritoneal dialysis prescription. Nephrol Dial Transplant. 2010;25:1633-8.
5. Johnson DW, Cho Y, Livingston BE, et al. Encapsulating peritoneal sclerosis: incidence, predictors, and outcomes. Kidney Int. 2010;77:904-12.
6. Yamamoto R, Otsuka Y, Nakayama M, et al. Risk factors for encapsulating peritoneal sclerosis in patients who have experienced peritoneal dialysis treatment. Clin Exp Nephrol. 2005;9:148-52.
7. Korte MR, Sampimon DE, Lingsma HF, et al. Risk factors associated with encapsulating peritoneal sclerosis in Dutch EPS Study. Perit Dial Int. 2011;31:269-78.
8. Lambie ML, John B, Mushahar L, Huckvale C, Davies SJ. The peritoneal osmotic conductance is low well before the diagnosis of encapsulating peritoneal sclerosis is made. Kidney Int. 2010;78:611-8.
9. Sampimon DE, Coester AM, Struijk DG, Krediet RT. The time course of peritoneal transport parameters in peritoneal dialysis patients who develop encapsulating peritoneal sclerosis. Nephrol Dial Transplant. 2011;26:291-8.
10. Jenkins SB, Leng BL, Shortland JR, Brown PW, Wilkie ME. Sclerosing encapsulating peritonitis: a case series from a single U.K. center during a 10-year period. Adv Perit Dial. 2001;17:191- 5.
11. Fieren MW, Betjes MG, Korte MR, Boer WH. Posttransplant encapsulating peritoneal sclerosis: a worrying new trend? Perit Dial Int. 2007;27:619-24.
12. Korte MR, Yo M, Betjes MG, et al. Increasing incidence of severe encapsulating peritoneal sclerosis after kidney transplantation. Nephrol Dial Transplant. 2007;22:2412-4.
13. Korte MR, Habib SM, Lingsma H, Weimar W, Betjes MG. Posttransplantation encapsulating peritoneal sclerosis contributes significantly to mortality after kidney transplantation. Am J Transplant. 2011;11:599-605.
14. Korte MR, Boeschoten EW, Betjes MG. The Dutch EPS Registry: increasing the knowledge of encapsulating peritoneal sclerosis. Neth J Med. 2009;67:359-62.
15. Summers AM, Abrahams AC, Alscher MD, et al. A collaborative approach to understanding eps: the European perspective. Perit Dial Int. 2011;31:245-8.
16. Dobbie JW. Pathogenesis of peritoneal fibrosing syndromes (sclerosing peritonitis) in peritoneal dialysis. Perit Dial Int. 1992;12:14-27.
17. Nakayama M. The plasma leak-to-response hypothesis: a working hypothesis on the pathogenesis of encapsulating peritoneal sclerosis after long-term peritoneal dialysis treatment. Perit Dial Int. 2005;25 Suppl 4:S71-6.
18. Kawanishi H, Harada Y, Noriyuki T, et al. Treatment options for encapsulating peritoneal sclerosis based on progressive stage. Adv Perit Dial. 2001;17:200-4.
19. Sherif AM, Yoshida H, Maruyama Y, et al. Comparison between the pathology of encapsulating sclerosis and simple sclerosis of the peritoneal membrane in chronic peritoneal dialysis. Ther Apher Dial. 2008;12:33-41.
20. Lopez-Cabrera M, Aguilera A, Aroeira LS, et al. Ex vivo analysis of dialysis effluent-derived mesothelial cells as an approach to unveiling the mechanism of peritoneal membrane failure. Perit Dial Int. 2006;26:26-34.
21. Aguilera A, Yanez-Mo M, Selgas R, Sanchez-Madrid F, Lopez-Cabrera M. Epithelial to mesenchymal transition as a triggering factor of peritoneal membrane fibrosis and angiogenesis in peritoneal dialysis patients. Curr Opin Investig Drugs. 2005;6:262-8.
22. Selgas R, Bajo A, Jimenez-Heffernan JA, et al. Epithelial-to-mesenchymal transition of the mesothelial cell--its role in the response of the peritoneum to dialysis. Nephrol Dial Transplant. 2006;21 Suppl 2:ii2-7.
23. Aroeira LS, Aguilera A, Sanchez-Tomero JA, et al. Epithelial to mesenchymal transition and peritoneal membrane failure in peritoneal dialysis patients: pathologic significance and potential therapeutic interventions. J Am Soc Nephrol. 2007;18:2004-13.
24. Io H, Hamada C, Ro Y, Ito Y, Hirahara I, Tomino Y. Morphologic changes of peritoneum and expression of VEGF in encapsulated peritoneal sclerosis rat models. Kidney Int. 2004;65:1927-36.
25. Kawanishi H, Watanabe H, Moriishi M, Tsuchiya S. Successful surgical management of encapsulating peritoneal sclerosis. Perit Dial Int. 2005;25 Suppl 4:S39-47.
26. Geurts N, Hubens G, Wojciechowski M, Vaneerdeweg W. Encapsulating peritoneal sclerosis in a peritoneal dialysis patient with prune-belly syndrome: a case report. Acta Chir Belg. 2010;110:354-6.
27. Kawaguchi Y, Kawanishi H, Mujais S, Topley N, Oreopoulos DG. Encapsulating peritoneal sclerosis: definition, etiology, diagnosis, and treatment. International Society for Peritoneal Dialysis Ad Hoc Committee on Ultrafiltration Management in Peritoneal Dialysis. Perit Dial Int. 2000;20 Suppl 4:S43-55.
28. Hendriks MP, de Sevaux RG, Hilbrands LB. Encapsulating peritoneal sclerosis in patients on peritoneal dialysis. Neth J Med. 2008;66:269-74.
29. Kawanishi H, Moriishi M. Encapsulating peritoneal sclerosis: prevention and treatment. Perit Dial Int. 2007;27 Suppl 2:S289-92.
30. Summers AM, Clancy MJ, Syed F, et al. Single-center experience of encapsulating peritoneal sclerosis in patients on peritoneal dialysis for end-stage renal failure. Kidney Int. 2005;68:2381-8.
31. Vlijm A, Stoker J, Bipat S, et al. Computed tomographic findings characteristic for encapsulating peritoneal sclerosis: a case-control study. Perit Dial Int. 2009;29:517-22.
32. Brown MC, Simpson K, Kerssens JJ, Mactier RA. Encapsulating peritoneal sclerosis in the new millennium: a national cohort study. Clin J Am Soc Nephrol. 2009;4:1222-9.
33. Tarzi RM, Lim A, Moser S, et al. Assessing the validity of an abdominal CT scoring system in the diagnosis of encapsulating peritoneal sclerosis. Clin J Am Soc Nephrol. 2008;3:1702-10.
34. Kropp J, Sinsakul M, Butsch J, Rodby R. Laparoscopy in the early diagnosis and management of sclerosing encapsulating peritonitis. Semin Dial. 2009;22:304-7.
35. Honda K, Nitta K, Horita S, et al. Histologic criteria for diagnosing encapsulating peritoneal sclerosis in continuous ambulatory peritoneal dialysis patients. Adv Perit Dial. 2003;19:169-75.
36. Kim BS, Choi HY, Ryu DR, et al. Clinical characteristics of dialysis related sclerosing encapsulating peritonitis: multi-center experience in Korea. Yonsei Med J. 2005;46:104-11.
37. Alscher DM, Reimold F. New facts about encapsulating peritoneal sclerosis as a sequel of long-term peritoneal dialysis - what can we do? Minerva Urol Nefrol. 2007;59:269-79.
38. Otsuka Y, Nakayama M, Ikeda M, et al. Restoration of peritoneal integrity after withdrawal of peritoneal dialysis: characteristic features of the patients at risk of encapsulating peritoneal sclerosis. Clin Exp Nephrol. 2005;9:315-9.
39. Nomoto Y, Kawaguchi Y, Kubo H, Hirano H, Sakai S, Kurokawa K. Sclerosing encapsulating peritonitis in patients undergoing continuous ambulatory peritoneal dialysis: a report of the Japanese Sclerosing Encapsulating Peritonitis Study Group. Am J Kidney Dis. 1996;28:420-7.
40. Nakayama M, Yamamoto H, Ikeda M, et al. Risk factors and preventive measures for encapsulating peritoneal sclerosis--Jikei experience 2002. Adv Perit Dial. 2002;18:144-8.
41. Moriishi M, Kawanishi H, Kawai T, et al. Preservation of peritoneal catheter for prevention of encapsulating peritoneal sclerosis. Adv Perit Dial. 2002;18:149-53.
42. Wong CF, Beshir S, Khalil A, Pai P, Ahmad R. Successful treatment of encapsulating peritoneal sclerosis with azathioprine and prednisolone. Perit Dial Int. 2005;25:285-7.
43. Lafrance JP, Letourneau I, Ouimet D, et al. Successful treatment of encapsulating peritoneal sclerosis with immunosuppressive therapy. Am J Kidney Dis. 2008;51:e7-10.
44. Rajani R, Smyth J, Koffman CG, Abbs I, Goldsmith DJ. Differential Effect of sirolimus vs prednisolone in the treatment of sclerosing encapsulating peritonitis. Nephrol Dial Transplant. 2002;17:2278-80.
45. Bozkurt D, Sipahi S, Cetin P, et al. Does immunosuppressive treatment ameliorate morphology changes in encapsulating peritoneal sclerosis? Perit Dial Int. 2009;29 Suppl 2:S206-10.
46. Kuriyama S, Tomonari H. Corticosteroid therapy in encapsulating peritoneal sclerosis. Nephrol Dial Transplant. 2001;16:1304-5.
47. Mori Y, Matsuo S, Sutoh H, Toriyama T, Kawahara H, Hotta N. A case of a dialysis patient with sclerosing peritonitis successfully treated with corticosteroid therapy alone. Am J Kidney Dis. 1997;30:275-8.
48. Dejagere T, Evenepoel P, Claes K, Kuypers D, Maes B, Vanrenterghem Y. Acute-onset, steroid-sensitive, encapsulating peritoneal sclerosis in a renal transplant recipient. Am J Kidney Dis. 2005;45:e33-7.
49. Martins LS, Rodrigues AS, Cabrita AN, Guimaraes S. Sclerosing encapsulating peritonitis: a case successfully treated with immunosuppression. Perit Dial Int. 1999;19:478-81.
50. Tan R, Betjes M, Cransberg K. Post-transplantation encapsulating peritoneal sclerosis in a young child. Nephrol Dial Transplant. 2011;26:3822-4.
51. Evrenkaya TR, Atasoyu EM, Unver S, Basekim C, Baloglu H, Tulbek MY. Corticosteroid and tamoxifen therapy in sclerosing encapsulating peritonitis in a patient on continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant. 2004;19:2423-4.
52. Korzets A, Ori Y, Zevin D, et al. A worrying thought--could there be a connection between encapsulating peritoneal sclerosis, tamoxifen and calciphylaxis? Nephrol Dial Transplant. 2006;21:2975-8.
53. Mahtosh P, Guest SS. Tuberculous Peritonitis Presenting as Encapsulating Peritoneal Sclerosis. Perit Dial Int. 2007;27:S19.
54. Savelli BA, Parshley M, Morganroth ML. Successful treatment of sclerosing cervicitis and fibrosing mediastinitis with tamoxifen. Chest. 1997;111:1137-40.
55. Hansmann A, Adolph C, Vogel T, Unger A, Moeslein G. High-dose tamoxifen and sulindac as first-line treatment for desmoid tumors. Cancer. 2004;100:612-20.
56. van Bommel EF, Hendriksz TR, Huiskes AW, Zeegers AG. Brief communication: tamoxifen therapy for nonmalignant retroperitoneal fibrosis. Ann Intern Med. 2006;144:101-6.
57. Kuhn MA, Wang X, Payne WG, Ko F, Robson MC. Tamoxifen decreases fibroblast function and downregulates TGF(beta2) in dupuytren's affected palmar fascia. J Surg Res. 2002;103:146-52.
58. Allaria PM, Giangrande A, Gandini E, Pisoni IB. Continuous ambulatory peritoneal dialysis and sclerosing encapsulating peritonitis: tamoxifen as a new therapeutic agent? J Nephrol. 1999;12:395-7.
59. Eltoum MA, Wright S, Atchley J, Mason JC. Four consecutive cases of peritoneal dialysis-related encapsulating peritoneal sclerosis treated successfully with tamoxifen. Perit Dial Int. 2006;26:203-6.
60. del Peso G, Bajo MA, Gil F, et al. Clinical experience with tamoxifen in peritoneal fibrosing syndromes. Adv Perit Dial. 2003;19:32-5.
61. Pollock CA. Bloody ascites in a patient after transfer from peritoneal dialysis to hemodialysis. Semin Dial. 2003;16:406-10.
62. Korte MR, Fieren MW, Sampimon DE, Lingsma HF, Weimar W, Betjes MG. Tamoxifen is associated with lower mortality of encapsulating peritoneal sclerosis: results of the Dutch Multicentre EPS Study. Nephrol Dial Transplant. 2011;26:691-7.
63. Balasubramaniam G, Brown EA, Davenport A, et al. The Pan-Thames EPS study: treatment and outcomes of encapsulating peritoneal sclerosis. Nephrol Dial Transplant. 2009;24:3209-15.
64. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet. 1998;351:1451-67.
65. Guest S. Tamoxifen therapy for encapsulating peritoneal sclerosis: mechanism of action and update on clinical experiences. Perit Dial Int. 2009;29:252-5.
66. Braun N, Fritz P, Biegger D, et al. Difference in the expression of hormone receptors and fibrotic markers in the human peritoneum--implications for therapeutic targets to prevent encapsulating peritoneal sclerosis. Perit Dial Int. 2011;31:291-300.
67. Moustafellos P, Hadjianastassiou V, Roy D, et al. Tamoxifen therapy in encapsulating sclerosing peritonitis in patients after kidney transplantation. Transplant Proc. 2006;38:2913-4.
68. Gupta S, Woodrow G. Successful treatment of fulminant encapsulating peritoneal sclerosis following fungal peritonitis with tamoxifen. Clin Nephrol. 2007;68:125-9.
69. Thirunavukarasu T, Saxena R, Anijeet H, Pai P, Wong CF. Encapsulating peritoneal sclerosis presenting with recurrent ascites and tamoxifen: case reports and review of the literature. Ren Fail. 2007;29:775-6.
70. Mesquita M, Guillaume MP, Dratwa M. First use of tamoxifen in an HIV patient with encapsulating peritoneal sclerosis. Clin Drug Investig. 2007;27:727-9.
71. Tulumovic D, Mesic E, Tulumovic A. Idiopathic retroperitoneal fibrosis: a rare onset of the illness caused by haemorrhagic fever with renal syndrome. Nephrol Dial Transplant. 2006;21:1450.
72. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90:1371-88.
73. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 2005;97:1652-62.
74. Augustine T, Brown P W, Davies S D, Summers A M, Wilkie M E. Encapsulating peritoneal sclerosis: clinical significance and implications. Nephron Clin Pract. 2009;111:c149-54; discussion c54.
75. Celicout B, Levard H, Hay J, Msika S, Fingerhut A, Pelissier E. Sclerosing encapsulating peritonitis: early and late results of surgical management in 32 cases. French Associations for Surgical Research. Dig Surg. 1998;15:697-702.
76. Kittur DS, Korpe SW, Raytch RE, Smith GW. Surgical aspects of sclerosing encapsulating peritonitis. Arch Surg. 1990;125:1626-8.
77. Kawanishi H, Ide K, Yamashita M, et al. Surgical techniques for prevention of recurrence after total enterolysis in encapsulating peritoneal sclerosis. Adv Perit Dial. 2008;24:51-5.
78. Yamamoto H, Nakayama M, Yamamoto R, et al. Fifteen cases of encapsulating peritoneal sclerosis related to peritoneal dialysis: a single-center experience in Japan. Adv Perit Dial. 2002;18:135-8.
79. Kirkman MA, Heap S, Mitu-Pretorian OM, et al. Posttransplant encapsulating peritoneal sclerosis localized to the terminal ileum. Perit Dial Int. 2010;30:480-2.
80. Suh WN, Lee SK, Chang H, et al. Sclerosing encapsulating peritonitis (abdominal cocoon) after abdominal hysterectomy. Korean J Intern Med. 2007;22:125-9.
81. Kawanishi H, Moriishi M, Ide K, Dohi K. Recommendation of the surgical option for treatment of encapsulating peritoneal sclerosis. Perit Dial Int. 2008;28 Suppl 3:S205-10.
82. de Freitas D, Jordaan A, Williams R, et al. Nutritional management of patients undergoing surgery following diagnosis with encapsulating peritoneal sclerosis. Perit Dial Int. 2008;28:271-6.
83. Yeun JY, Kaysen GA. Factors influencing serum albumin in dialysis patients. Am J Kidney Dis. 1998;32:S118-25.
84. Marra AR, Opilla M, Edmond MB, Kirby DF. Epidemiology of bloodstream infections in patients receiving long-term total parenteral nutrition. J Clin Gastroenterol. 2007;41:19-28.